PND44 Cost-Utility Analysis and Cost-Minimisation Analysis of Sabril® (Vigabatrin) in Drug-Resistant Epilepsy From Payer's Perspective in Poland
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1968
https://www.valueinhealthjournal.com/article/S1098-3015(12)03681-9/fulltext
Title :
PND44 Cost-Utility Analysis and Cost-Minimisation Analysis of Sabril® (Vigabatrin) in Drug-Resistant Epilepsy From Payer's Perspective in Poland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03681-9&doi=10.1016/j.jval.2012.08.1968
First page :
A553
Section Title :
Neurological Disorders
Open access? :
No
Section Order :
1452